药物对比
Alogliptin vs Sotagliflozin
Alogliptin vs Sotagliflozin：治疗2型糖尿病的DPP-4抑制剂vs双重SGLT抑制剂。比较血糖控制、心力衰竭风险、心血管获益及安全性。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered for type 2 diabetes patients with cardiovascular disease or heart failure when choosing between a DPP-4 inhibitor and a dual SGLT inhibitor.
结论
Sotagliflozin often suits those with heart failure or CV risk better, while Alogliptin may suffice for straightforward glycemic control, but individual factors decide.
全部药物对比